4//SEC Filing
Koppel Adam 4
Accession 0000899243-21-032893
CIK 0001773427other
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 8:38 PM ET
Size
10.7 KB
Accession
0000899243-21-032893
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2021-08-10$70.25/sh−1,000,000$70,250,000→ 4,831,307 total(indirect: See footnotes)
Holdings
- 1,106
Common Stock
BC SW, LP
10% Owner
Transactions
- Sale
Common Stock
2021-08-10$70.25/sh−1,000,000$70,250,000→ 4,831,307 total(indirect: See footnotes)
Holdings
- 1,106
Common Stock
Schwartz Jeffrey Lawrence
Director10% Owner
Transactions
- Sale
Common Stock
2021-08-10$70.25/sh−1,000,000$70,250,000→ 4,831,307 total(indirect: See footnotes)
Holdings
- 1,106
Common Stock
Koppel Adam
10% Owner
Transactions
- Sale
Common Stock
2021-08-10$70.25/sh−1,000,000$70,250,000→ 4,831,307 total(indirect: See footnotes)
Holdings
- 1,106
Common Stock
Footnotes (4)
- [F1]Represents shares of common stock held directly by BC SW, LP.
- [F2]Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, LP. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, LP. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.
- [F3]Jeffrey Schwartz is a director of the Issuer.
- [F4]Represents a restricted stock award held directly by Jeffrey Schwartz.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
Related Parties
1- filerCIK 0001578965
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 8:38 PM ET
- Size
- 10.7 KB